Surprisingly, Lipitor share is tracking below historical generic substitution patterns from the past few years, i.e., the brand-name version is losing share faster than a typical generic drug.
The chart below tells the story, which is about as unexpected as an overweight, butter-loving celebrity chef becoming the spokesperson for a manufacturer of diabetes medicine. Oh, wait...
Based on IMS data, Larry Marsh at Barclays Capital reported yesterday that atorvastatin, the generic form of Lipitor, controlled 67.4% of the Lipitor market for the week ending January 6, 2012. This is the fifth full reported week by IMS with atorvastatin on the market.
The chart below compares Lipitor to a broad sample of generic drugs from the past 5 years. To create it, I combined the following two sources:
- Page 21 from the IMS Institute for Healthcare Informatics' The Use of Medicines in the United States report
- The IMS prescription data for Lipitor, as reported by Barclays Capital yesterday
I'll check back in a few months and see where things stand. In the meantime, I'll be managing my weight and cholesterol levels by eating a burger, egg, bacon, and donut sandwich.